Zuventus Healthcare Limited on Tuesday moved to calm market speculation after reports and informal communications surfaced suggesting a possible closure or rebranding of the company. The pharmaceutical firm issued a formal clarification categorically denying the claims and reaffirming that its operations remain stable and fully functional. In its statement, Zuventus said there has been no closure, suspension, or transfer of its business assets. The company underlined that its field force continues to operate at full strength across India, indicating uninterrupted market activity and normal engagement with healthcare professionals and partners.
Zuventus also addressed market chatter linking it to Zorvia Healthcare Limited, stating clearly that it has no association or affiliation with any such entity. The company described these claims as inaccurate and misleading, noting that they have the potential to create confusion among stakeholders. Founded in 2002, Zuventus Healthcare is a subsidiary of Emcure Pharmaceuticals, which is listed on the Bombay Stock Exchange and the National Stock Exchange. The company reiterated its long-standing focus on developing, manufacturing, and marketing high-quality and affordable medicines in the Indian market.
As part of its response, Zuventus said it is actively pursuing appropriate legal remedies to protect its goodwill and business interests from the spread of misinformation. From a market perspective, Zuventus maintains a strong position in branded generics, with a diversified portfolio covering cardiology, diabetology, gastroenterology, orthopaedics, pain management, and nutraceuticals. Supported by robust manufacturing standards, a growing field workforce, and a patient-centric strategy, the company said it remains committed to strengthening its presence and maintaining trust across India’s healthcare ecosystem.
